Product Information
PIOGLITAZONE HCL 30 MG TABLET is a generic product labeled by Major Pharmaceuticals, priced at $0.0930 per EA under NDC 00904709661. Its NADAC has been published 293 times since Feb 24, 2021.
FDA first approved this application on Feb 13, 2013. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
30 mg/1
Manufacturer
Major PharmaceuticalsNDC
00904709661
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PIOGLITAZONE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA200268FDA Approved
2/13/2013
TE Code
AB
On Market Since
2/13/2013
Pharmacological Classes
Price Statistics
The NADAC for PIOGLITAZONE HCL 30 MG TABLET has been published 293 times since Feb 24, 2021, and over the history we have for it it has declined 42.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0930 per EA |
|---|---|
| All-time high | $0.1603 (Mar 10, 2021) |
| All-time low | $0.0828 (Nov 20, 2024) |
| 52-week high | $0.0981 |
| 52-week low | $0.0888 |
| Median price | $0.1130 |
| Average price | $0.1140 |
| Largest weekly change | +24.7% (Jun 19, 2024) |
| Weeks tracked | 293 |
| Tracking since | Feb 24, 2021 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Major Pharmaceuticals manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Pioglitazone market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Peroxisome Proliferator Receptor alpha Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PIOGLITAZONE HCL 30 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for PIOGLITAZONE HCL 30 MG TABLET, manufactured by Major Pharmaceuticals, is $0.0930 per EA (NDC 00904709661), effective Sep 30, 2026.
How has the price of PIOGLITAZONE HCL 30 MG TABLET changed over time?
Over the history we have for it, the NADAC for PIOGLITAZONE HCL 30 MG TABLET has declined 42.0%. It has been tracked across 293 weekly CMS publications since Feb 24, 2021.
What are the highest and lowest recorded NADAC prices for PIOGLITAZONE HCL 30 MG TABLET?
Since Feb 24, 2021, the NADAC for PIOGLITAZONE HCL 30 MG TABLET has ranged from a low of $0.0828 (Nov 20, 2024) to a high of $0.1603 (Mar 10, 2021), with a median of $0.1130 per EA.
Are there cheaper alternatives to PIOGLITAZONE HCL 30 MG TABLET?
5 manufacturers publish a NADAC-priced product with the same active ingredient and strength as PIOGLITAZONE HCL 30 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures PIOGLITAZONE HCL 30 MG TABLET?
PIOGLITAZONE HCL 30 MG TABLET (NDC 00904709661) is labeled by Major Pharmaceuticals, and CMS classifies it as a generic product.